All AbMole products are for research use only, cannot be used for human consumption.
AR-231453 enhances glucose-induced insulin release. Antidiabetic activity. AR-231453 is Orally active in vivo. The GPR119-specific agonist AR231453 significantly increased cAMP accumulation and insulin release in both HIT-T15 cells and rodent islets. In both cases, loss of GPR119 rendered AR231453 inactive. AR231453 also enhanced glucose-dependent insulin release in vivo and improved oral glucose tolerance in wild-type mice but not in GPR119-deficient mice. Diabetic KK/A(y) mice were also highly responsive to AR231453.
| Molecular Weight | 505.50 |
| Formula | C21H24FN7O5S |
| CAS Number | 733750-99-7 |
| Solubility (25°C) | DMSO |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related GPR/FFAR Products |
|---|
| GW9508
GW9508 is a potent and selective G protein-coupled receptors FFA1 (GPR40) and GPR120 agonist with pEC50s of 7.32 and 5.46, respectively. GW9508 has anti-inflammatory and anti-atherosclerotic activities. GW9508 is a glucose-sensitive insulin secretagogue and an ATP-sensitive potassium (KATP) channels opener. |
| Fasiglifam (TAK-875) Hemihydrate
Fasiglifam (TAK-875) Hemihydrate is a novel, orally available, selective GPR40 agonist. |
| OC000459
OC000459 is a potent, selective, and orally active D prostanoid receptor 2 antagonist. |
| AMG-837
AMG 837 is a potent, orally bioavailable GPR40 agonist with EC50 of 14 nM. |
| AZD1981
AZD1981 is a potent, selective CRTh2 (DP2) receptor antagonist with IC50 of 4 nM, showing >1000-fold selectivity over more than 340 other enzymes and receptors, including DP1. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
